Vanoxerine
- Generic Name
- Vanoxerine
- Drug Type
- Small Molecule
- Chemical Formula
- C28H32F2N2O
- CAS Number
- 67469-69-6
- Unique Ingredient Identifier
- 90X28IKH43
- Background
Vanoxerine is a highly selective dopamine transporter antagonist. It was synthesized in the late 1970s and developed as a potential treatment for depression. Vanoxerine was later evaluated as a potential treatment for cocaine addiction due to its ability to block dopamine reuptake with a slower dissociation rate than cocaine. Although several studies have suggested that the profile of vanoxerine is safer than that of cocaine, other studies have found that vanoxerine has at least moderate potential to be abused by humans. More recently, vanoxerine was tested as a potential anti-arrhythmic and anti-atrial fibrillatory agent due to its ability to block the hKV11.1 (hERG) cardiac potassium channel. Vanoxerine is an investigational drug and has not been approved for therapeutic use.
- Indication
Vanoxerine has not been approved for therapeutic use.
Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
- Conditions
- Atrial Fibrillation or Flutter
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Laguna Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02454283
Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
- Conditions
- Symptomatic Atrial FibrillationAtrial Flutter
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Laguna Pharmaceuticals, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT01691313
Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 3
- Registration Number
- NCT00218049
- Locations
- 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States
Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1
- Conditions
- Cocaine-Related Disorders
- First Posted Date
- 2004-12-23
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 24
- Registration Number
- NCT00100113
- Locations
- 🇺🇸
U of Texas Medical Branch Galveston, Galveston, Texas, United States
GBR 12909 Study in Cocaine Experienced African American Volunteers - 1
- Conditions
- Cocaine-Related Disorders
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 10
- Registration Number
- NCT00089687
- Locations
- 🇺🇸
Uniformed Services University of Health Science, Bethesda, Maryland, United States
Assessment of the Potential Interactions Between Cocaine and GBR 12909 - 1
- Conditions
- Cocaine-Related Disorders
- First Posted Date
- 2003-01-20
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 24
- Registration Number
- NCT00051896
- Locations
- 🇺🇸
Uniformed Services University of Health Science, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.